ANDA 85855, held by Hospira. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 85855 (A-Methapred), held by Hospira, was first approved by FDA on Mar 28, 1978, with 16 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 1978 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| A-MethapredEQ 125MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Oct 11, 2002 | Supplement 35Labeling | Approved | None posted |
| Oct 23, 1997 | Supplement 34Manufacturing | Approved | None posted |
| Jul 28, 1997 | Supplement 33Manufacturing | Approved | None posted |
| Feb 7, 1996 | Supplement 31Manufacturing | Approved | None posted |
| Mar 25, 1994 | Supplement 30Labeling | Approved | None posted |
| Oct 15, 1993 | Supplement 29Manufacturing | Approved | None posted |
| Aug 12, 1993 | Supplement 28Labeling | Approved | None posted |
| Mar 25, 1991 | Supplement 26Labeling | Approved | None posted |
| Mar 25, 1991 | Supplement 27Labeling | Approved | None posted |
| Nov 20, 1990 | Supplement 24Manufacturing | Approved | None posted |
| Apr 23, 1986 | Supplement 22Manufacturing | Approved | None posted |
| Dec 24, 1984 | Supplement 21Manufacturing | Approved | None posted |
| Apr 19, 1984 | Supplement 14Manufacturing | Approved | None posted |
| Jan 20, 1984 | Supplement 12Manufacturing | Approved | None posted |
| Jan 20, 1984 | Supplement 13Manufacturing | Approved | None posted |
| Feb 23, 1979 | Supplement 1Manufacturing | Approved | None posted |
| Mar 28, 1978 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters